164 related articles for article (PubMed ID: 28219443)
21. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry.
El-Beshlawy A; Tylki-Szymanska A; Vellodi A; Belmatoug N; Grabowski GA; Kolodny EH; Batista JL; Cox GF; Mistry PK
Mol Genet Metab; 2017; 120(1-2):47-56. PubMed ID: 28040394
[TBL] [Abstract][Full Text] [Related]
22. Gaucher disease and the clinical experience with substrate reduction therapy.
Zimran A; Elstein D
Philos Trans R Soc Lond B Biol Sci; 2003 May; 358(1433):961-6. PubMed ID: 12803930
[TBL] [Abstract][Full Text] [Related]
23. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
Duan YL; Zhang YH; Zang Y; Shi HP; Zhang WM; Hu YM
Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
[TBL] [Abstract][Full Text] [Related]
24. Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients.
Smid BE; Ferraz MJ; Verhoek M; Mirzaian M; Wisse P; Overkleeft HS; Hollak CE; Aerts JM
Orphanet J Rare Dis; 2016 Mar; 11():28. PubMed ID: 27008851
[TBL] [Abstract][Full Text] [Related]
25. Gaucher disease: unmet treatment needs.
Mehta A
Acta Paediatr; 2008 Apr; 97(457):83-7. PubMed ID: 18339195
[TBL] [Abstract][Full Text] [Related]
26. Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imiglucerase.
Smith L; Rhead W; Charrow J; Shankar SP; Bavdekar A; Longo N; Mardach R; Harmatz P; Hangartner T; Lee HM; Crombez E; Pastores GM
Mol Genet Metab; 2016 Feb; 117(2):164-71. PubMed ID: 26043810
[TBL] [Abstract][Full Text] [Related]
27. Imino sugar therapy for type 1 Gaucher disease.
Priestman DA; Platt FM; Dwek RA; Butters TD
Glycobiology; 2000 Nov; 10(11):iv-vi. PubMed ID: 11221677
[No Abstract] [Full Text] [Related]
28. [Clinical study of the French cohort of Gaucher disease patients].
Stirnemann J
Rev Med Interne; 2006 Mar; 27 Suppl 1():S18-21. PubMed ID: 16644396
[TBL] [Abstract][Full Text] [Related]
29. Results from a 9-year Intensive Safety Surveillance Scheme (IS(3) ) in miglustat (Zavesca(®) )-treated patients.
Brand M; Muller A; Alsop J; van Schaik IN; Bembi B; Hughes D
Pharmacoepidemiol Drug Saf; 2015 Mar; 24(3):329-33. PubMed ID: 25656910
[TBL] [Abstract][Full Text] [Related]
30. Velaglucerase alfa for the management of type 1 Gaucher disease.
Morris JL
Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
[TBL] [Abstract][Full Text] [Related]
31. [Osteoarticular manifestations of Gaucher disease in adults: pathophysiology and treatment].
Javier RM; Hachulla E
Presse Med; 2007 Dec; 36(12 Pt 3):1971-84. PubMed ID: 17498916
[TBL] [Abstract][Full Text] [Related]
32. Individualized long-term enzyme therapy for Gaucher disease type 1 in Slovenia.
Benedik-Dolničar M; Kitanovski L
Pediatr Int; 2011 Dec; 53(6):1018-22. PubMed ID: 21883686
[TBL] [Abstract][Full Text] [Related]
33. Guidance on the use of miglustat for treating patients with type 1 Gaucher disease.
Weinreb NJ; Barranger JA; Charrow J; Grabowski GA; Mankin HJ; Mistry P
Am J Hematol; 2005 Nov; 80(3):223-9. PubMed ID: 16247743
[TBL] [Abstract][Full Text] [Related]
34. Changes of bone metabolism in seven patients with Gaucher disease treated consecutively with imiglucerase and miglustat.
Mikosch P; Reed M; Baker R; Holloway B; Berger L; Mehta AB; Hughes DA
Calcif Tissue Int; 2008 Jul; 83(1):43-54. PubMed ID: 18553043
[TBL] [Abstract][Full Text] [Related]
35. Seven-year safety and efficacy with velaglucerase alfa for treatment-naïve adult patients with type 1 Gaucher disease.
Zimran A; Wang N; Ogg C; Crombez E; Cohn GM; Elstein D
Am J Hematol; 2015 Jul; 90(7):577-83. PubMed ID: 25903392
[TBL] [Abstract][Full Text] [Related]
36. An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment.
Pastores GM; Barnett NL; Kolodny EH
Clin Ther; 2005 Aug; 27(8):1215-27. PubMed ID: 16199246
[TBL] [Abstract][Full Text] [Related]
37. [New data on Gaucher's disease].
Stirnemann J
Rev Med Interne; 2008 Mar; 29(3):176-8. PubMed ID: 17964006
[No Abstract] [Full Text] [Related]
38. Combination therapy in a patient with chronic neuronopathic Gaucher disease: a case report.
Ceravolo F; Grisolia M; Sestito S; Falvo F; Moricca MT; Concolino D
J Med Case Rep; 2017 Jan; 11(1):19. PubMed ID: 28103924
[TBL] [Abstract][Full Text] [Related]
39. Long term effects of enzyme replacement therapy in an Italian cohort of type 3 Gaucher patients.
Sechi A; Deroma L; Dardis A; Ciana G; Bertin N; Concolino D; Linari S; Perria C; Bembi B
Mol Genet Metab; 2014 Nov; 113(3):213-8. PubMed ID: 25127542
[TBL] [Abstract][Full Text] [Related]
40. Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease.
Hollak CE; vom Dahl S; Aerts JM; Belmatoug N; Bembi B; Cohen Y; Collin-Histed T; Deegan P; van Dussen L; Giraldo P; Mengel E; Michelakakis H; Manuel J; Hrebicek M; Parini R; Reinke J; di Rocco M; Pocovi M; Sa Miranda MC; Tylki-Szymanska A; Zimran A; Cox TM
Blood Cells Mol Dis; 2010 Jan; 44(1):41-7. PubMed ID: 19804996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]